Bharat Parenterals Q1 FY27 Investor Presentation
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Bharat Parenterals Q1 FY27 consolidated revenue 93.7 Cr, down 19% YoY. EBITDA 8.5 Cr at 9.1% margin, PAT loss 3.6 Cr. Standalone revenue 55.5 Cr fell 41% YoY against prior year opening tranche of the 210 Cr institutional order, contract lifecycle not demand loss. Subsidiaries Innoxel 21.4 Cr up 165% YoY and Varenyam Healthcare 25.1 Cr up 52% showed strong growth. FY27 guidance: BPL standalone 10-15% growth at 10-15% EBITDA, Innoxel 35-45% growth at 20-25% EBITDA, Varenyam Healthcare 20-25% growth. Order book 171 Cr.
Mixed quarter — standalone weak on contract timing, but subsidiaries scaling fast. FY27 guides signal margin recovery as Innoxel commercial supply begins Q2.